CLDI Calidi Biotherapeutics, Inc.: institutional ownership and insider trading
20 funds reported holding $121K of Calidi Biotherapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net sold $252K, with 4 new positions and 9 funds selling out; over the last 12 months insiders bought $0 and sold $1.24K on the open market.
CLDI revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$4.16M, EPS -2.94
- Quarter ended Mar 31, 2026: revenue n/a, net income −$4.11M, EPS -0.43
- Quarter ended Dec 31, 2025: revenue n/a, net income −$4.06M, EPS 30.22
- Quarter ended Sep 30, 2025: revenue n/a, net income −$5.15M, EPS -2.21
Largest institutional holders of CLDI
- VANGUARD GROUP INC — $40.6K
- GEODE CAPITAL MANAGEMENT, LLC — $19.5K
- HighTower Advisors, LLC — $14.2K
- JANE STREET GROUP, LLC — $9.23K
- Independent Advisor Alliance — $7.65K
- Arax Advisory Partners — $6.35K
- Private Advisor Group, LLC — $5.10K
- VANGUARD CAPITAL MANAGEMENT LLC — $4.34K
- Belpointe Asset Management LLC — $3.39K
- NORTHERN TRUST CORP (NTRS, NTRSO) — $3.02K
Recent CLDI insider trades
- Dec 12, 2025: Camaisa Allan sold 850 shares ($1.24K)
- Aug 21, 2025: Poma Eric E bought 25,000 shares ($50.0K)
- Aug 21, 2025: Leftwich Scott bought 125,000 shares ($250K)
- Aug 21, 2025: Jackson Andrew C. bought 2,500 shares ($5.00K)
5%+ owners
- Armistice Capital, LLC: 10.0% (Schedule 13G, filed May 15, 2026)
Who owns the most CLDI stock?
The largest institutional holders of Calidi Biotherapeutics, Inc. in the latest 13F filings are VANGUARD GROUP INC ($40.6K), GEODE CAPITAL MANAGEMENT, LLC ($19.5K), HighTower Advisors, LLC ($14.2K).
Are insiders buying or selling CLDI?
Over the last 12 months insiders bought $0 and sold $1.24K of Calidi Biotherapeutics, Inc. stock on the open market (SEC Form 4).